XZP-5610

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameXZP-5610
Drug Alias NameXZP-5610
ClassificationSmall molecules
Mechanisms of ActionBile acid receptor FXR agonists
TargetsBile acid receptor FXR
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, SclerosingLiver Cirrhosis, Biliary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesXuanzhu (HK) Biopharmaceutical Ltd
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, SclerosingLiver Cirrhosis, Biliary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A